You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Type 2 Diabetes Mellitus:,MOUNJARO is indicated for the treatment of adults with insufficiently controlled type 2
diabetes mellitus as an adjunct to diet and exercise, as monotherapy when metformin is not tolerated or contraindicated., in addition to other medicinal products for the treatment of type 2 diabetes.,Chronic Weight Management,MOUNJARO is indicated as an adjunct to a reduced-calorie diet and increased physical activity
for chronic weight management, including weight loss and weight maintenance, in adults
with an initial body mass index (BMI) of:, =30 kg/m2 (obesity) or, =27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related
comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea,
cardiovascular disease, prediabetes or type 2 diabetes mellitus).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Type 2 Diabetes Mellitus:,MOUNJARO is indicated for the treatment of adults with insufficiently controlled type 2
diabetes mellitus as an adjunct to diet and exercise, as monotherapy when metformin is not tolerated or contraindicated., in addition to other medicinal products for the treatment of type 2 diabetes.,Chronic Weight Management,MOUNJARO is indicated as an adjunct to a reduced-calorie diet and increased physical activity
for chronic weight management, including weight loss and weight maintenance, in adults
with an initial body mass index (BMI) of:, =30 kg/m2 (obesity) or, =27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related
comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea,
cardiovascular disease, prediabetes or type 2 diabetes mellitus).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Type 2 Diabetes Mellitus:,MOUNJARO is indicated for the treatment of adults with insufficiently controlled type 2
diabetes mellitus as an adjunct to diet and exercise, as monotherapy when metformin is not tolerated or contraindicated., in addition to other medicinal products for the treatment of type 2 diabetes.,Chronic Weight Management,MOUNJARO is indicated as an adjunct to a reduced-calorie diet and increased physical activity
for chronic weight management, including weight loss and weight maintenance, in adults
with an initial body mass index (BMI) of:, =30 kg/m2 (obesity) or, =27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related
comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea,
cardiovascular disease, prediabetes or type 2 diabetes mellitus).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Type 2 Diabetes Mellitus:,MOUNJARO is indicated for the treatment of adults with insufficiently controlled type 2
diabetes mellitus as an adjunct to diet and exercise, as monotherapy when metformin is not tolerated or contraindicated., in addition to other medicinal products for the treatment of type 2 diabetes.,Chronic Weight Management,MOUNJARO is indicated as an adjunct to a reduced-calorie diet and increased physical activity
for chronic weight management, including weight loss and weight maintenance, in adults
with an initial body mass index (BMI) of:, =30 kg/m2 (obesity) or, =27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related
comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea,
cardiovascular disease, prediabetes or type 2 diabetes mellitus).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Type 2 Diabetes Mellitus:,MOUNJARO is indicated for the treatment of adults with insufficiently controlled type 2
diabetes mellitus as an adjunct to diet and exercise, as monotherapy when metformin is not tolerated or contraindicated., in addition to other medicinal products for the treatment of type 2 diabetes.,Chronic Weight Management,MOUNJARO is indicated as an adjunct to a reduced-calorie diet and increased physical activity
for chronic weight management, including weight loss and weight maintenance, in adults
with an initial body mass index (BMI) of:, =30 kg/m2 (obesity) or, =27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related
comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea,
cardiovascular disease, prediabetes or type 2 diabetes mellitus).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Type 2 Diabetes Mellitus:,MOUNJARO is indicated for the treatment of adults with insufficiently controlled type 2
diabetes mellitus as an adjunct to diet and exercise, as monotherapy when metformin is not tolerated or contraindicated., in addition to other medicinal products for the treatment of type 2 diabetes.,Chronic Weight Management,MOUNJARO is indicated as an adjunct to a reduced-calorie diet and increased physical activity
for chronic weight management, including weight loss and weight maintenance, in adults
with an initial body mass index (BMI) of:, =30 kg/m2 (obesity) or, =27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related
comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea,
cardiovascular disease, prediabetes or type 2 diabetes mellitus).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
